

Supplementary Method S1

Title: Implementation of a self-sampling HPV test for non-responders to cervical cancer screening in Japan: secondary analysis of the ACCESS trial

Authors: Misuzu Fujita^{1,2}, Kengo Nagashima^{3,4}, Minobu Shimazu⁵, Misae Suzuki⁶, Ichiro Tauchi⁶, Miwa Sakuma⁶, Setsuko Yamamoto⁶, Hideki Hanaoka⁵, Makio Shozu⁷, Nobuhide Tsuruoka⁸, Tokuzo Kasai¹, Akira Hata^{1,9}

Affiliations: ¹Department of Health Research, Chiba Foundation for Health Promotion and Disease Prevention, Chiba 261-0002, Japan; ²Department of Public Health, Chiba University Graduate School of Medicine, Chiba 260-8670, Japan; ³Biostatistics Unit, Clinical and Translational Research Center, Keio University Hospital, Shinju-ku, Tokyo 160-8582, Japan; ⁴Research Center for Medical and Health Data Science, The Institute of Statistical Mathematics, Tachikawa, Tokyo 190-8562, Japan; ⁵Clinical Research Center, Chiba University Hospital, Chiba 260-8677, Japan; ⁶Municipal Health Center, Department of Health and Welfare, Ichihara City, Ichihara, Chiba 290-0050, Japan; ⁷Departments of Reproductive Medicine, Chiba University Graduate School of Medicine, Chiba 260-0856, Japan; ⁸Yushudai Clinic, Ichihara, Chiba 299-0125, Japan; ⁹Center for Preventive Medical Sciences, Chiba University, Chiba 260-0826, Japan

Endpoints of this secondary analysis

Proportion of self-sampling human papillomavirus (HPV) tests ordered

The percentage of the participants who ordered the self-sampling HPV test was calculated. The denominator is the intention to screen (ITS) in the self-sampling arm, which includes all participants who were assigned to the self-sampling arm. The numerator is the number of participants who ordered the test.

Proportion of self-sampling HPV tests ordered through the website

The percentage of the participants who ordered the test through the website, in which the denominator is all participants who ordered the test, and the numerator is those who ordered through the website, was calculated.

Proportion of self-sampling HPV test kits returned

The proportions of the participants who underwent an HPV test with two different denominators and one numerator were calculated. The denominators are ITS in the self-sampling arm and the number of participants who ordered self-sampling HPV tests. The numerator is the number of participants who return both a sample and a filled consent form.

Proportion of positive HPV tests

The percentage of participants with a positive HPV test result was defined as the detection of DNA of the 14 high-risk HPV types (types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68). The denominator is the number of participants who returned both a sample and a filled consent form. The numerator is the number of participants with a positive HPV test result.

Proportion of invalid HPV tests

The percentage of participants whose HPV test result was invalid was defined as the failure to detect DNA of the 14 high-risk HPV types and β -globin (internal cellular control). The denominator is the number of participants who returned both a sample and a filled consent form. The numerator is the number of participants whose HPV test result was invalid.

Time-to-event

Time to order the test

The period between the time that the second invitation letter was sent to the participants and the time that the self-sampling HPV test was ordered by the participants was calculated. The participants to be analyzed were those who ordered the test.

Time to send a kit

The period between the time that the self-sampling HPV test was ordered and the time that the kit was sent to the participants was calculated. The participants to be analyzed were those who ordered the self-sampling HPV test.

Time to return a sample since sending the kit

The period between the time that the kit was sent to the participants and the time a sample was returned was calculated. The participants to be analyzed were those who returned both a sample and a filled consent form, and these participants were named “participants A.”

Time to return a sample since collecting it

The period between the time that a sample was collected by the participants and the time that

the sample was returned was calculated. The participants to be analyzed were those who returned both a sample and a filled consent form and reported the sample collection date.

Time to order the test to the laboratory

The period between the time that a sample was returned by the participants and the HPV test was ordered to the laboratory was calculated. The participants to be analyzed were “participants A.”

Time for the laboratory to report the results

The period between the time that the HPV test was ordered to the laboratory and the results were reported by the laboratory was calculated. The participants to be analyzed were “participants A.”

Time to send the results to the participants

The period between the time that the results were reported by the laboratory and the results were sent to the participants was calculated. The participants to be analyzed were “participants A.”

Total time

The total period between the time that the second invitation letter was sent to the participants and the time that the HPV test results were sent to the participants was calculated. The participants to be analyzed were “participants A.”

Incidence of adverse events

If adverse events were claimed by the participants, the percentage of those with adverse event(s) was calculated. The denominator is the number of participants who returned both a sample and a filled consent form. The numerator is the number of participants who reported each type of adverse event.